Navigation Links
Gene Network Sciences Awarded Patent Covering REFS(TM) Platform
Date:5/4/2009

CAMBRIDGE, Mass., May 4 /PRNewswire/ -- Gene Network Sciences, Inc. (GNS) today announced that it has been awarded U.S. Patent No. 7,512,497, entitled "Systems and Methods for Inferring Biological Networks." The patent covers GNS's core model learning and simulation platform, REFS(TM) (Reverse Engineering and Forward Simulation).

GNS has deployed the REFS(TM) platform in several collaborations with pharmaceutical and biotechnology companies and academic and clinical institutions in diseases areas such as oncology, rheumatoid arthritis, cardiovascular and metabolic disease, and Alzheimer's disease. The REFS(TM) platform, which is run on supercomputers, enables the rapid extraction of actionable, patient-specific knowledge directly from experimental and clinical data.

"We have now extended our patent portfolio beyond our previous issued patents covering an ultra-efficient language to model known biology and the simulation of known pathways, to the fully data-driven inference and simulation of novel biology," said Tom Neyarapally, Senior Vice President of Corporate Development for GNS. "GNS now has broad intellectual property coverage across our modeling and simulation activities."

GNS has several other pending patent applications addressing the REFS(TM) platform and its use in areas of application in biological systems and areas outside of biology such as quantitative finance, online advertising, and natural resource exploration, as well as applications covering drug targets, biomarkers, and diagnostic markers discovered using the REFS(TM) platform.

About Gene Network Sciences

Gene Network Sciences (http://www.gnsbiotech.com/) is a leader in biosimulation with its ability to derive molecular mechanisms of drugs and diseases directly from molecular profiling and clinical data. Based in Cambridge, Massachusetts, and Ithaca, New York, GNS uses its REFS(TM) technology in pharmaceutical and clinical settings to rapidly turn combinations of genetic, genomic, and clinical measurements into models of disease progression and drug response. These models are then simulated to discover both new targets for drug intervention and genetic markers of drug response that allow patients who will respond to a given drug treatment to be matched to a particular clinical trial. By discovering how and why specific sets of genes and drug candidates impact human biology, GNS technology enables the rapid development of breakthrough drug and diagnostic products.


'/>"/>
SOURCE Gene Network Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Living Network Announces Launch of New Blood Sugar Web Site
2. Blue Cross Blue Shield of Michigan and Blue Care Network Launch Web Sites to Help Chrysler Members Easily Find Information on Their Health Care
3. Technologically Advanced Digital Handheld Device Positions Network Global Logistics as Technology Leader in Last Mile Delivery Solutions
4. Healthy Living Network Announces Launch of New Supplement Information Web Site
5. Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB
6. Diversified Agency Services Network Launches TogoRun(TM), A New Global Healthcare Communications Agency
7. Insurers Administrative Corporation Joins the Availity Network
8. Anthem Blue Cross and Blue Shield and Middlesex Hospital Renew Network Agreement
9. Health Caring - A Network of Strength
10. Family Healthcare Network Selects InteGreat EHR for Deployment of Browser-Based EHR
11. Agito Networks Named to the First Annual InformationWeek Startup 50 Listing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... March 29, 2017 , ... ... pharmacist Dr. Isabella Wentz, Pharm.D., FASCP. The program was recently launched on March ... common questions regarding thyroid function. , Dr. Izabella Wentz is a licensed ...
(Date:3/28/2017)... NY (PRWEB) , ... March 28, 2017 , ... ... process management software and services, is proud to announce it has joined the ... professional association representing the interests of chronically ill, disabled, and dying Americans of ...
(Date:3/28/2017)... ... March 28, 2017 , ... Alert Sentry Group LLC., a leader in the ... Systems), the iSAFE and the iSAFE Plus. These iSAFE products are the most affordable ... the iSAFE and iSAFE Plus offer direct GPS Location and two-way calling with the ...
(Date:3/28/2017)... ... 28, 2017 , ... Usually, the impending arrival of warmer weather means the ... about a double chin, this means more anxiety than elation. The cosmetic dermatology experts ... people, a double chin is undesirable,” Dr. Goldman said, “but it seems doubly so ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... leading physicians, Paul Yost, will begin serving as new board chair for Orange ... month. Yost will serve the remainder of soon-to-be former chair Mark Refowitz’s term, ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... TORONTO , March 28, 2017 /PRNewswire/ - StarFish ... medical device development firm, announced today that it has ... -based medical device industrial design and productization organization.  ... throughout North America with easier ... talent spanning the design, engineering, regulatory, and manufacturing process. ...
(Date:3/28/2017)... March 28, 2017  Akcea Therapeutics, a subsidiary of Ionis ... company,s board of directors: ... Gabrieli will serve as chairman of the board of Akcea ... commercial officer of Forest Laboratories. Sandford ... "We are excited to announce this ...
(Date:3/28/2017)... , March 28, 2017 ... to reach USD 8.0 billion by 2025, according to ... increasing incidence of infectious diseases and cancer is expected ... in disease diagnosis over the coming years. In addition, ... of autologous and allogenic stem cell therapy, due to ...
Breaking Medicine Technology: